The Impact of Suboxone's Market Exclusivity on Cost of Opioid Use Disorder Treatment.
Meghan McGeeKellia ChiuRahim MoineddinAbhimanyu SudPublished in: Applied health economics and health policy (2023)
Unmerited 6 years of market exclusivity for brand-name buprenorphine-naloxone in Canada resulted in substantial excess costs. There is an urgent need to implement policies that can help reduce costs for high-priority drugs in Canada.
Keyphrases